It was found that emodin treatment at 30–90 μM markedly reversed afatinib (20 nM) resistance and promoted apoptosis via suppressing STAT3 and EGFR expression in pancreatic cancer cells (PANC-1 and BxPC-3) [149]. Here, EGFR is linked to pancreatic neoplasm.